GSK’s Nucala approved in China as add-on therapy for adults with CRSwNP
GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that targets interleukin-5,
GSK's Sinus Disease Drug Secures Approval In China
On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on therapy with intranasal corticosteroids for adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP) for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.
GSK Nucala approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps
London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an
GSK gets approval in China for Nucala for rhinosinusitis
GSK (NYSE:GSK) has received Chinese regulatory approval for its drug Nucala, also known as mepolizumab, for the treatment of adults with inadequately controlled chronic rhinosinusitis with nasal polyps,
GSK’s Nucala Gains Approval in China for CRSwNP
GlaxoSmithKline ( (GSK) ) has provided an update. GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP),
GSK’s Nucala wins wider approval in China
China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK pharma major GSK that targets interleukin-5 (IL-5).
GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps
GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Saturday, January 4, 2025, 09:00 Hrs [IST] GSK plc announced
GSK's Nucala gets third approval in China
GSK announced on Friday that its monoclonal antibody ‘Nucala’, or mepolizumab, has received approval from China's National Medical Products Administration for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults.
Monthly Prescribing Reference28d
Mepolizumab Under Review for Eosinophilic COPD
Credit: Getty images Mepolizumab is an interleukin-5 antagonist monoclonal antibody. A Prescription Drug User Fee Act target date of May 7, 2025 has been assigned to the application. The Food and ...
Business Insider27d
GSK: FDA Accepts For Review Submission For New Indication Of Nucala In COPD
The Prescription Drug User Fee Act (PDUFA) date is May 7, 2025. Mepolizumab is a monoclonal antibody that targets and binds to interleukin-5 (IL-5), a key messenger protein (cytokine) in type 2 ...
Seeking Alpha29d
Upstream Bio: Attractive, But Let's Wait For More Data And Lock-Up Expiry
Verekitug, a TSLP receptor inhibitor, shows higher efficacy in reducing FeNO and eosinophils compared to competitors like Tezepelumab, Dupilumab, and Mepolizumab. With a market cap of $1.18bn and ...
EurekAlert!21d
Mepolizumab and benralizumab mode of action (IMAGE)
Diagrammatic illustration of the mechanism of two monoclonal antibodies utilized for treating eosinophilic asthma, mepolizumab, and benralizumab. Mepolizumab specifically targets interleukin-5 (IL ...